Replimune Shares Sink After FDA Rejects Skin-Cancer Drug a Second Time
The CEO was just on CNBC calling out the FDA and wondering why they rejected their drug. He is calling for an investigation into the rejection. This could get interesting as the CEO says this could potentially put the company out of business and a treatment off the market for people who have no options left for melanoma.
The company also included data from IGNYTE showing median progression free survival on RP1 plus nivolumab was 30.6 months in responding patients compared to 4.4 months on their prior PD-1 based regimen.
https://finance.yahoo.com/sectors/healthcare/...00877.html